Integra LifeSciences shares drop 17% on revenue miss and probe
- Shares fell 17% on Oct 2, 2026, after Q3 revenue missed consensus
- Preliminary Q3 revenue of $410M-$412M short of $416.3M estimate
- FY26 revenue guidance cut to $1.634B-$1.654B due to Cincinnati flood
- SueWallSt investigating potential misleading statements on flood impact
*this image is generated using AI for illustrative purposes only.
Integra LifeSciences Holdings Corporation shares fell sharply on October 2, 2026, after preliminary third-quarter revenue of $410 million to $412 million missed the FactSet consensus estimate of $416.3 million. The shortfall triggered a pending investigation by SueWallSt into potential securities claims.
The medical technology company lowered its full-year 2026 financial guidance, citing a $7 million revenue impact in the third quarter from a July flooding event at its Cincinnati manufacturing facility. The company now expects third-quarter adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results reflect operational disruptions affecting products within the Specialty Surgical Technologies portfolio.
Guidance revisions and flood impact
The company updated its full-year revenue outlook to a range of $1.634 billion to $1.654 billion, down from the previous range of $1.654 billion to $1.695 billion. Adjusted earnings per diluted share guidance was reduced to $2.30 to $2.40, compared to the prior estimate of $2.40 to $2.50.
Stuart Essig, Chairman and Chief Executive Officer, stated that the team has made significant progress in executing recovery plans. The company estimates the supply disruption will negatively impact fourth-quarter revenue by approximately $15 million to $20 million. Full manufacturing operations at the site are expected to resume in the second quarter of 2027.
Investigation into prior statements
SueWallSt notified investors of a pending investigation following the stock's decline. Shares opened down $2.79 per share, or about 17%, and fell further to near 20% by midday. The investigation concerns whether statements Integra made about its manufacturing operations and projected results may have been misleading.
During the previous earnings call on July 29, 2026, Chief Financial Officer Lea Daniels Knight informed investors the company did not expect the flooding event to have a material impact on revenue or EPS guidance for 2026. The subsequent disclosure of surprise revenue impacts contradicted this earlier assessment, leading to the alleged inflation of share prices before the October 2 disclosure.
Cash flow and insurance recovery
Despite the revenue reduction, Integra expects strong cash generation, with operating cash flow projected at approximately $190 million to $200 million for the full year. Third-quarter operating cash flow is expected to exceed $85 million. The company maintains property and business interruption insurance, which it anticipates will mitigate a substantial portion of the earnings impact during the recovery period.
What the numbers show
The guidance cut highlights a divergence between top-line pressure and bottom-line resilience. While revenue guidance was lowered by up to $41 million at the midpoint ($1.6745 billion vs $1.644 billion), the adjusted EPS guidance midpoint fell by only $0.05 ($2.45 vs $2.35). This suggests that insurance recoveries and cost management are effectively shielding profitability from the direct revenue loss caused by the facility outage.
| Metric | Previous Guidance | Updated Guidance | Change |
|---|---|---|---|
| FY26 Revenue | $1.654B - $1.695B | $1.634B - $1.654B | Lowered |
| FY26 Adj. EPS | $2.40 - $2.50 | $2.30 - $2.40 | Lowered |
| Q3FY26 Revenue | N/A | $410M - $412M | Preliminary |
| Q3FY26 Adj. EPS | N/A | $0.55 - $0.59 | Preliminary |
| FY26 Op. Cash Flow | N/A | $190M - $200M | Disclosed |
Integra will report its final third-quarter results in October 2026.
How will the anticipated insurance recoveries impact Integra's free cash flow trajectory in fiscal 2027 once the Cincinnati facility is fully operational?
What specific regulatory or legal precedents might influence the outcome of the SueWallSt investigation regarding the CFO's prior guidance on materiality?
Will the prolonged supply disruption in Specialty Surgical Technologies create permanent market share losses to competitors before full capacity resumes in Q2 2027?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
